Robertson Stephens Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Robertson Stephens Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-636	Closed	-$491K	–	653
2025 Q4	$491K	Buy	+636	New	+$432K	0.01%	430
2024 Q4	–	Sell	-303	Closed	-$319K	–	627
2024 Q3	$319K	Buy	303 +56	+23%	+$62.3K	0.01%	515
2024 Q2	$260K	Buy	+247	New	+$239K	0.01%	440
2023 Q1	–	Sell	-356	Closed	-$257K	–	459
2022 Q4	$257K	Sell	356 -10	-3%	-$7.38K	0.03%	358
2022 Q3	$252K	Buy	366 +10	+3%	+$6.29K	0.03%	310
2022 Q2	$210K	Sell	356 -59	-14%	-$38.4K	0.02%	356
2022 Q1	$289K	Buy	+415	New	+$263K	0.02%	318
2020 Q4	–	Sell	-690	Closed	-$386K	–	260
2020 Q3	$386K	Buy	+690	New	+$418K	0.09%	158

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Robertson Stephens Wealth Management's REGN Position: Q1 2026 in Review

Robertson Stephens Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 636 shares — an estimated $491K sold.

Robertson Stephens Wealth Management first reported a position in REGN in Q3 2020 and held it in 8 quarters. The position peaked at $491K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Robertson Stephens Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Robertson Stephens Wealth Management sold 636 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $491K.
Robertson Stephens Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Robertson Stephens Wealth Management's Regeneron Pharmaceuticals position peaked at $491K in Q4 2025.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.